Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about SANOFI
01/19 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/15 SANOFI : Disclosure of trading in own shares
01/15 SANOFI : Pasteur to return $27.8 million to Philippine government
01/09 ALNYLAM PHARMACEUTICALS : Sanofi restructure RNAi therapeutics deal
01/08 SANOFI : Disclosure of trading in own shares
01/08 SANOFI : Disclosure of trading in own shares
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/08 CELGENE CORPORATION (NASDAQ : CELG) Kicks Off J.P. Morgan With A Bang
01/08 SANOFI : and Regeneron to accelerate and expand investment for cemiplimab and du..
01/08 Celgene gets JAK-2 inhibitor in Impact deal
01/08 SANOFI : And Alnylam Restructure RNAi Therapeutics Rare Disease Alliance
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
01/07 SANOFI : and Alnylam enter into strategic restructuring of RNAi therapeutics rar..
01/07 SANOFI : and Alnylam enter into strategic restructuring of RNAi therapeutics rar..
More most relevant news
All news about SANOFI
01/20 SANOFI : refunds gov't with P1.16-B for unused Dengvaxia
01/20 SANOFI : refunds P1.16-B worth of unused Dengvaxia
01/20 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Researchers from Sanofi Pasteur Report Findings in Mycoplasma (Validati..
01/19 SANOFI : Researchers from Sanofi Pasteur Describe Findings in Rabies Virus (A no..
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/19 NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights From Phase III...
01/18 SANOFI : EDITORIAL - Sober approach
01/18 SANOFI : NBI to submit initial result of probe on Dengvaxia mess
More news
Sector news : Pharmaceuticals - NEC
01/19 CANADIAN CANNABIS FIRM AURORA IN TAL : sources
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/17 VERTEX PHARMACEUTICALS : Set To Wow In '18
01/16 WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
Latest Tweets
06:21aDuque: Sanofi not yet off the hook after refund for unused Dengvaxia
8
01/20DENGVAXIA VACCINE: Gordon wants transparency in DOH-Sanofi discussions
12
01/20Syntal Capital Partners LLC Takes Position in Regeneron Pharmaceuticals Inc $.. 
01/20Sanofi asked to provide P2B in escrow to cover hospitalization of vaccinees -.. 
01/20Sanofi Appoints Dominique Carouge Executive Vice President Head of Business T.. 
More tweets
Qtime:153
Financials (€)
Sales 2017 35 761 M
EBIT 2017 9 145 M
Net income 2017 7 967 M
Debt 2017 5 749 M
Yield 2017 4,14%
P/E ratio 2017 11,54
P/E ratio 2018 16,05
EV / Sales 2017 2,74x
EV / Sales 2018 2,69x
Capitalization 92 146 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 83,9 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI0.72%112 597
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132